iShares NASDAQ Biotechnology Index (ETF) 

(Public, NASDAQ:IBB)   Watch this stock   
Find more results forAMEX:IBB

Key stats and ratios

Q1 (Mar '09) 2009
Net profit margin -7663.70% -2845.84%
Operating margin 22.81% 14.28%
EBITD margin - -
Return on average assets -38.90% -15.48%
Return on average equity -44.40% -18.10%

Address

525 Washington Boulevard Suite 1405
Jersey City, NJ 07310
United States - Map
+1-800-4742737 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

iShares NASDAQ Biotechnology Index (ETF) discussions

  View all discussions »

Description

iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund’s investment advisor is Barclays Global Fund Advisors, a subsidiary of Barclays Global Investors, N.A.

Officers and directors

Lee T. Kranefuss
Chairman of the Board, President, Trustee of iShares Trust.
Age: 48
Bio & Compensation - Reuters
Michael A. Latham
Principal Financial Officer, Treasurer, Secretary
Age: 44
Bio & Compensation - Reuters
Richard K. Lyons
Trustee of iShares Trust
Age: 48
Bio & Compensation - Reuters
Jhon F. Martinez
Trustee of iShares Trust
Age: 47
Bio & Compensation - Reuters
George G. C. Parker Ph.D.
Trustee of iShares Trust
Age: 70
Bio & Compensation - Reuters
W. Allen Reed
Trustee of iShares Trust
Age: 62
Bio & Compensation - Reuters
Cecilia H. Herbert
Trustee of iShares Trust
Age: 60
Bio & Compensation - Reuters